ES2983565T3 - Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes - Google Patents

Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes Download PDF

Info

Publication number
ES2983565T3
ES2983565T3 ES14852359T ES14852359T ES2983565T3 ES 2983565 T3 ES2983565 T3 ES 2983565T3 ES 14852359 T ES14852359 T ES 14852359T ES 14852359 T ES14852359 T ES 14852359T ES 2983565 T3 ES2983565 T3 ES 2983565T3
Authority
ES
Spain
Prior art keywords
dexmedetomidine
subject
transdermal delivery
delivery device
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14852359T
Other languages
English (en)
Spanish (es)
Inventor
Adchara Pongpeerapat
Amit Jain
Bret Berner
Jianye Wen
Jutaro Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Application granted granted Critical
Publication of ES2983565T3 publication Critical patent/ES2983565T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES14852359T 2013-10-07 2014-10-03 Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes Active ES2983565T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887871P 2013-10-07 2013-10-07
PCT/US2014/059058 WO2015054063A1 (en) 2013-10-07 2014-10-03 Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions

Publications (1)

Publication Number Publication Date
ES2983565T3 true ES2983565T3 (es) 2024-10-23

Family

ID=52777130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14852359T Active ES2983565T3 (es) 2013-10-07 2014-10-03 Métodos y composiciones para tratar los síndromes de abstinencia mediante el uso de composiciones transdérmicas de dexmedetomidina no sedantes

Country Status (11)

Country Link
US (1) US20150098983A1 (cg-RX-API-DMAC7.html)
EP (1) EP3054934B1 (cg-RX-API-DMAC7.html)
JP (1) JP6231670B2 (cg-RX-API-DMAC7.html)
KR (2) KR101881791B1 (cg-RX-API-DMAC7.html)
CN (1) CN105682650B (cg-RX-API-DMAC7.html)
CA (1) CA2924190C (cg-RX-API-DMAC7.html)
ES (1) ES2983565T3 (cg-RX-API-DMAC7.html)
FI (1) FI3054934T3 (cg-RX-API-DMAC7.html)
RU (1) RU2648817C2 (cg-RX-API-DMAC7.html)
TW (1) TWI624278B (cg-RX-API-DMAC7.html)
WO (1) WO2015054063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI709417B (zh) * 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
GB201600918D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
KR20190060007A (ko) * 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
WO2020006119A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
MX2021004737A (es) * 2018-10-24 2021-06-04 Saniona As Composiciones de tropano transdermicas y metodos para usar las mismas.
CA3135552C (en) * 2019-04-17 2023-09-26 Lts Lohmann Therapie-Systeme Ag Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
CN121401263A (zh) 2020-02-14 2026-01-27 帝国制药美国公司 外用纳洛酮组合物及其使用方法
JP2023545372A (ja) * 2020-10-08 2023-10-30 バイオエクセル セラピューティクス,インコーポレイテッド デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
WO2022147537A1 (en) * 2021-01-04 2022-07-07 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens
CN115227638B (zh) * 2022-07-19 2025-03-18 广州新济生物医药研究院有限公司 一种盐酸右美托咪定可溶性微针及其制备方法
US20240207285A1 (en) * 2022-12-20 2024-06-27 Melt Pharmaceuticals, Inc. Midazolam and ketamine for enhanced sedation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP4687897A2 (en) * 2023-04-04 2026-02-11 Board of Regents, The University of Texas System Combinations including methocinnamox

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
ES2228125T3 (es) * 1998-10-02 2005-04-01 3M Innovative Properties Company Sistemas de suministro de farmacos originados en las mucosas.
US20030170195A1 (en) * 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
EP1652508B1 (en) * 2003-07-31 2013-12-04 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
JP4148988B2 (ja) * 2006-09-11 2008-09-10 積水化学工業株式会社 貼付剤
JP5547065B2 (ja) * 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20130072532A1 (en) * 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
CA2815898C (en) * 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2013072763A2 (en) * 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ES2663412T3 (es) * 2012-01-31 2018-04-12 Grünenthal GmbH Parche farmacéutico para la administración transdérmica de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina

Also Published As

Publication number Publication date
TW201521799A (zh) 2015-06-16
EP3054934A4 (en) 2017-04-05
CA2924190C (en) 2019-07-09
JP2016532643A (ja) 2016-10-20
WO2015054063A1 (en) 2015-04-16
EP3054934A1 (en) 2016-08-17
US20150098983A1 (en) 2015-04-09
RU2648817C2 (ru) 2018-03-28
JP6231670B2 (ja) 2017-11-15
KR101881791B1 (ko) 2018-07-25
EP3054934B1 (en) 2024-05-22
KR20180021902A (ko) 2018-03-05
BR112016006200A2 (pt) 2017-08-01
CA2924190A1 (en) 2015-04-16
FI3054934T3 (fi) 2024-07-19
CN105682650A (zh) 2016-06-15
TWI624278B (zh) 2018-05-21
CN105682650B (zh) 2020-09-25
RU2016109632A (ru) 2017-11-15
KR20160055934A (ko) 2016-05-18

Similar Documents

Publication Publication Date Title
CA2924190C (en) Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
ES2856748T3 (es) Dispositivos de administración transdérmica de dexmedetomidina y métodos para el uso de los mismos
CA3038354C (en) Methods of managing pain using dexmedetomidine transdermal delivery devices
US10874642B2 (en) Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
ES2847936T3 (es) Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
ES2855103T3 (es) Dispositivo de suministro transdérmico para el control del dolor que comprende composiciones transdérmicas de dexmedetomidina
CN111447927A (zh) 纳洛酮经皮给药装置及其使用方法
BR112016006200B1 (pt) Uso de dispositivo de distribuição transdérmica para tratar síndrome de abstinência
HK40018815A (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
BR112016007327B1 (pt) Uso de dispositivo de distribuição transdérmica para controlar dor
HK40033308A (en) Naloxone transdermal drug-delivery devices and methods for using the same
BR112016006971B1 (pt) Uso de dispositivo de distribuição transdérmica no tratamento de transtorno de déficit de atenção e hiperatividade (tdah), ansiedade ou insônia
WO2020084065A1 (en) Transdermal tropane compositions and methods for using the same